Genetic Testing

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorNearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE…

1 year ago
GeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on YearGeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on Year

GeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on Year

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

1 year ago
Multicancer Screening Market Projected to Reach $2.72 billion by 2030 – Exclusive Report by 360iResearchMulticancer Screening Market Projected to Reach $2.72 billion by 2030 – Exclusive Report by 360iResearch

Multicancer Screening Market Projected to Reach $2.72 billion by 2030 – Exclusive Report by 360iResearch

PUNE, India, April 15, 2024 /PRNewswire/ -- The report titled "Multicancer Screening Market by Product (AI and Machine Learning-Based Platforms,…

1 year ago
CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators ListCancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

CHICAGO--(BUSINESS WIRE)--#aheadofcancer--CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of…

1 year ago
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight TestingMyriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight testSALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE)…

1 year ago
EVENT – Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”EVENT – Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”

EVENT – Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”

MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…

1 year ago
Shifa Health Marks 21 Years of Transformative Mental Health CareShifa Health Marks 21 Years of Transformative Mental Health Care

Shifa Health Marks 21 Years of Transformative Mental Health Care

A Celebration of Innovation, Compassion, and Community EngagementEVERETT, WA / ACCESSWIRE / April 3, 2024 / Shifa Health, a leading…

1 year ago
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight…

1 year ago
GENE to develop Worlds Most Advanced Comprehensive Risk Test  Revolutionising Personalised HealthcareGENE to develop Worlds Most Advanced Comprehensive Risk Test  Revolutionising Personalised Healthcare

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based…

1 year ago
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production StartApplied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start

Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start

- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods -- Project Slated for Completion Coincident with…

1 year ago